Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with relapsing-remitting multiple sclerosis (RRMS), a type of MS where symptoms come and go in episodes
- People who have shown a specific type of memory difficulty (trouble retrieving memories) based on neuropsychological testing done at the research lab
- People who can speak and read English fluently
Who may not be able to join:
- People who have had an MS relapse, a sudden worsening of MS symptoms, or a course of steroid treatment within the two months before testing
- People who take benzodiazepines (a type of sedative or anti-anxiety medication) unless they have been on a stable dose for at least two months
- People who have certain other brain or neurological conditions, including dementia, epilepsy or seizure disorders, severe traumatic brain injury, a brain tumour, stroke, abnormal blood vessels in the brain, Parkinson's disease, or Huntington's disease
- People who are currently misusing drugs or substances
- People who are unable to give informed consent to participate
- People who have metal implants in the skull or head area
- People who have skull defects that would interfere with the brain stimulation technique used in this trial (confirm with trial site)
- People who are taking certain medications that may interact with the brain stimulation used in this trial, including anti-seizure medications, L-dopa, carbamazepine, sulpiride, pergolide, lorazepam, rivastigmine, dextromethorphan, D-cycloserine, flunarizine, or ropinirole
- People taking stimulant medications such as dextroamphetamine, amphetamine, modafinil, or armodafinil would need to stop taking them during the trial period (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: John Hart, Jr, MD, The University of Texas at Dallas
Phone: 972-833-3161
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Treatment group differences in change from Baseline to 1-week Post-Treatment on Category Fluency; Treatment group differences in change from Baseline to 2-months Post-Treatment on Category Fluency; Treatment group differences in change from Baseline to 1-week Post-Treatment on COWAT; Treatment group differences in change from Baseline to 2-months Post-Treatment on COWAT
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.